Interleukin-6 (IL-6) is a 26-kDa secretory protein composed of 184 amino acids and two N-glycosylation sites, as well as four cysteine residues in the mature IL-6.

This article summarized the latest R&D progress of Cyclopentolate Hydrochloride, the Mechanism of Action for Cyclopentolate Hydrochloride, and the drug target R&D trends for Cyclopentolate Hydrochloride.

Orchard Therapeutics, a renowned leader in gene therapy worldwide, reported that the U.S. FDA has approved the submission of their BLA for OTL-200.

This article summarized the latest R&D progress of Cyanamide, the Mechanism of Action for Cyanamide, and the drug target R&D trends for Cyanamide.

Kadcyla is an antibody-drug conjugate (ADC) used as a single-agent treatment for HER2-positive metastatic breast cancer patients. The article introduces the specific operational methods for patent retrieval of the ADC drug Kadcyla.

This article summarized the latest R&D progress of Colestipol Hydrochloride, the Mechanism of Action for Colestipol Hydrochloride, and the drug target R&D trends for Colestipol Hydrochloride.

Rani Therapeutics Holdings proclaimed the launch of a Phase 1 clinical investigation assessing the safety and tolerability of RT-111.

This article summarized the latest R&D progress of Cholic Acid, the Mechanism of Action for Cholic Acid, and the drug target R&D trends for Cholic Acid.

IDH2, or isocitrate dehydrogenase 2, is an enzyme that plays a crucial role in cellular metabolism.

This article summarized the latest R&D progress of Chlortetracycline, the Mechanism of Action for Chlortetracycline, and the drug target R&D trends for Chlortetracycline.

LAPIX Therapeutics, Inc. announced U.S. FDA clearance of its IND application. The approval enables Phase 1 trials for its leader compound, LPX-TI641, aimed at treating multiple sclerosis.

This article summarized the latest R&D progress of Ceritinib, the Mechanism of Action for Ceritinib, and the drug target R&D trends for Ceritinib.